Immune checkpoint inhibitors (ICIs) are specialized monoclonal antibodies (mAbs) that
target immune checkpoints and their ligands, counteracting cancer cell-induced T-cell …

Epstein-Barr virus (EBV) is a prevalent oncogenic virus estimated to infect greater than 90%
of the world's population. Following initial infection, it establishes latency in host B cells. EBV …

Objective This study was designed to assess the efficacy and safety of cadonilimab
monotherapy, a first-in-class, bi-specific PD-1/CTLA-4 antibody, in patients with previously …

Sequential immunotherapy has shown certain advantages in malignancy. Here, we aim to
evaluate the efficacy of sequential anti-CTLA-4 and anti-PD-1 treatment for recurrent or …

Metal-ion therapy is an emerging technique for cancer treatment, where anticancer metals
trigger an immune response against tumor cells due to immunogenic cell death while …

Simple Summary In the dynamic landscape of nasopharyngeal carcinoma (NPC)
management, this review delves into a spectrum of radiotherapy (RT) practices, ranging from …

摘要尽管随着以调强放疗为主的综合治疗的广泛开展, 鼻咽癌的复发率较传统二维放疗时代已经
明显降低, 但仍有相当一部分患者会在根治性放疗后出现复发. 复发鼻咽癌(rNPC) …

Abstract Treatment options are limited for patients with recurrent or metastatic
nasopharyngeal carcinoma (RM-NPC) after failure to anti-PD-1 therapy. Cadonilimab …

Immune checkpoint inhibitors (ICIs) represent a promising class of monoclonal antibodies
designed to target immune checkpoints (ICs) and their ligands, thereby counteracting cancer …

Introduction There is a need to improve the outcomes of patients with head and neck
squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC), especially in …